Comparative Effectiveness of Abaloparatide and Teriparatide in Women 50 Years of Age and Older: Update of a Real-World Retrospective Analysis

What Was Tested

This observational study looks at Abaloparatide and Teriparatide.

The researchers conducted a retrospective claims study to examine the incidences of hip and nonvertebral fractures and cardiovascular events in women aged ≥50 years initiating abaloparatide or teriparatide therapy, expanding on a previous retrospective claims study.

Why It Was Studied

Abaloparatide and teriparatide are osteoanabolic treatments indicated for postmenopausal women and men with osteoporosis at high risk of fracture.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, older adults and people over 80, women only.

This retrospective observational study used anonymized claims data from ICON's Symphony Health, PatientSource for women aged ≥ 50 years with ≥ 1 prescription fill for abaloparatide or teriparatide.

How the Study Was Run

The index date was the date of the initial prescription dispensed.

What Was Measured

Topics PubMed links to this paper include Teriparatide, Parathyroid Hormone-Related Protein, Bone Density Conservation Agents, Hip Fractures, Osteoporotic Fractures and Osteoporosis.

The authors tagged it with the keywords abaloparatide and nonvertebral fracture.

What This Means in Plain Language

This is an observational study of Abaloparatide and Teriparatide.

The abstract goes on to report its results in about 7 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2025 (Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists), a journal based in United States.

More context: the Abaloparatide compound page and the Teriparatide compound page, all human trials.